An up­start in the poly­clon­al an­ti­body biz just lined up $50M for its plan to dis­rupt a multi­bil­lion-dol­lar busi­ness

The multi­bil­lion-dol­lar busi­ness for im­muno­glo­bin prod­ucts is dom­i­nat­ed by three key play­ers: CSL, Shire and Gri­fols.  And one of them re­cent­ly in­vest­ed $50 mil­lion in a South San Fran­cis­co-based biotech that thinks it has a key to dis­rupt­ing the en­tire glob­al mar­ket.

The com­pa­ny is a lit­tle known pri­vate play­er called Gi­ga­Gen. It has all of 10 staffers who are now so close­ly packed in­to their work space that the com­pa­ny will have to find new digs to ex­pand in­to. But it has glob­al am­bi­tions to do some­thing com­plete­ly new in poly­clon­al an­ti­bod­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER